GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses

Sean D. Donevan, Michael A Rogawski

Research output: Contribution to journalArticle

330 Citations (Scopus)

Abstract

In whole-cell voltage-clamp recordings from cultured rat hippocampal neurons, the 2,3-benzodiazepine GYKI 52466 was a potent antagonist of kainate- and AMPA-activated currents (IC50 values, 7.5 and 11 μM, respectively), but was inactive against N-methyl-d-aspartate (NMDA) or γ-aminobutyric acid responses. The block produced by GYKI 52466 occurred in a noncompetitive fashion, was voltage independent, and failed to show use dependence, indicating an allosteric blocking mechanism. In kinetic experiments with kainate as the agonist, the GYKI 52466 binding and unbinding rates were 1.6 × 105 M-1 s-1 and 3.2 s-1, respectively. GYKI 52466 also suppressed non-NMDA receptor-mediated spontaneous synaptic currents via a postsynaptic action. Noncompetitive AMPA/kainate antagonists such as GYKI 52466 could offer advantages over competitive antagonists in the treatment of glutamate-associated neurological disorders, particularly under conditions in which high levels of the amino acid would render the competitive antagonists relatively ineffective. Moreover, the results demonstrate the existence of a novel recognition site for an atypical benzodiazepine on non-NMDA receptors.

Original languageEnglish (US)
Pages (from-to)51-59
Number of pages9
JournalNeuron
Volume10
Issue number1
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Kainic Acid Receptors
AMPA Receptors
Benzodiazepines
Kainic Acid
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Aminobutyrates
Nervous System Diseases
Aspartic Acid
Inhibitory Concentration 50
Glutamic Acid
GYKI 52466
Neurons
Amino Acids

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. / Donevan, Sean D.; Rogawski, Michael A.

In: Neuron, Vol. 10, No. 1, 1993, p. 51-59.

Research output: Contribution to journalArticle

@article{7ab7534ce27c4b679f4c62ddf1fcdb68,
title = "GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses",
abstract = "In whole-cell voltage-clamp recordings from cultured rat hippocampal neurons, the 2,3-benzodiazepine GYKI 52466 was a potent antagonist of kainate- and AMPA-activated currents (IC50 values, 7.5 and 11 μM, respectively), but was inactive against N-methyl-d-aspartate (NMDA) or γ-aminobutyric acid responses. The block produced by GYKI 52466 occurred in a noncompetitive fashion, was voltage independent, and failed to show use dependence, indicating an allosteric blocking mechanism. In kinetic experiments with kainate as the agonist, the GYKI 52466 binding and unbinding rates were 1.6 × 105 M-1 s-1 and 3.2 s-1, respectively. GYKI 52466 also suppressed non-NMDA receptor-mediated spontaneous synaptic currents via a postsynaptic action. Noncompetitive AMPA/kainate antagonists such as GYKI 52466 could offer advantages over competitive antagonists in the treatment of glutamate-associated neurological disorders, particularly under conditions in which high levels of the amino acid would render the competitive antagonists relatively ineffective. Moreover, the results demonstrate the existence of a novel recognition site for an atypical benzodiazepine on non-NMDA receptors.",
author = "Donevan, {Sean D.} and Rogawski, {Michael A}",
year = "1993",
doi = "10.1016/0896-6273(93)90241-I",
language = "English (US)",
volume = "10",
pages = "51--59",
journal = "Neuron",
issn = "0896-6273",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses

AU - Donevan, Sean D.

AU - Rogawski, Michael A

PY - 1993

Y1 - 1993

N2 - In whole-cell voltage-clamp recordings from cultured rat hippocampal neurons, the 2,3-benzodiazepine GYKI 52466 was a potent antagonist of kainate- and AMPA-activated currents (IC50 values, 7.5 and 11 μM, respectively), but was inactive against N-methyl-d-aspartate (NMDA) or γ-aminobutyric acid responses. The block produced by GYKI 52466 occurred in a noncompetitive fashion, was voltage independent, and failed to show use dependence, indicating an allosteric blocking mechanism. In kinetic experiments with kainate as the agonist, the GYKI 52466 binding and unbinding rates were 1.6 × 105 M-1 s-1 and 3.2 s-1, respectively. GYKI 52466 also suppressed non-NMDA receptor-mediated spontaneous synaptic currents via a postsynaptic action. Noncompetitive AMPA/kainate antagonists such as GYKI 52466 could offer advantages over competitive antagonists in the treatment of glutamate-associated neurological disorders, particularly under conditions in which high levels of the amino acid would render the competitive antagonists relatively ineffective. Moreover, the results demonstrate the existence of a novel recognition site for an atypical benzodiazepine on non-NMDA receptors.

AB - In whole-cell voltage-clamp recordings from cultured rat hippocampal neurons, the 2,3-benzodiazepine GYKI 52466 was a potent antagonist of kainate- and AMPA-activated currents (IC50 values, 7.5 and 11 μM, respectively), but was inactive against N-methyl-d-aspartate (NMDA) or γ-aminobutyric acid responses. The block produced by GYKI 52466 occurred in a noncompetitive fashion, was voltage independent, and failed to show use dependence, indicating an allosteric blocking mechanism. In kinetic experiments with kainate as the agonist, the GYKI 52466 binding and unbinding rates were 1.6 × 105 M-1 s-1 and 3.2 s-1, respectively. GYKI 52466 also suppressed non-NMDA receptor-mediated spontaneous synaptic currents via a postsynaptic action. Noncompetitive AMPA/kainate antagonists such as GYKI 52466 could offer advantages over competitive antagonists in the treatment of glutamate-associated neurological disorders, particularly under conditions in which high levels of the amino acid would render the competitive antagonists relatively ineffective. Moreover, the results demonstrate the existence of a novel recognition site for an atypical benzodiazepine on non-NMDA receptors.

UR - http://www.scopus.com/inward/record.url?scp=0027404879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027404879&partnerID=8YFLogxK

U2 - 10.1016/0896-6273(93)90241-I

DO - 10.1016/0896-6273(93)90241-I

M3 - Article

VL - 10

SP - 51

EP - 59

JO - Neuron

JF - Neuron

SN - 0896-6273

IS - 1

ER -